Physician trust, early screening reduces disparities for prostate cancer

July 29, 2009

Men who have a regular, ongoing relationship with a health care provider are more likely to receive prostate cancer screening and less likely to be diagnosed with advanced prostate cancer, regardless of their race, according to a University of North Carolina study published in the current issue of the journal Cancer.

The study compared the experiences of black and white men over age 50 and newly diagnosed with prostate cancer in North Carolina and Louisiana. The goal was to find underlying reasons why African-American men have a higher incidence of prostate cancer and a higher rate of death from the disease than their white counterparts.

"We found that Caucasian (white) men tended to be seen regularly by the same physician, which appears to be associated with greater trust in their doctors and in physicians in general," said study author William R. Carpenter, Ph.D., research assistant professor of health policy and management in the UNC Gillings School of Global Public Health and a member of UNC Lineberger Comprehensive Cancer Center. "They were also more likely than their African-American counterparts to get regular prostate cancer screenings, and to get all their medical care at a physician's office."

The study enrolled 1,031 black and white men, age 50 and older, within weeks of their prostate cancer diagnosis. A study nurse conducted a structured survey and acquired biological specimens in a home visit and obtained other medical information from each patient's medical records.

In this study, the stage of prostate cancer at diagnosis was similar between races, but the mean Gleason scores, an indication of the aggressiveness of the disease, were higher for blacks than for whites. Blacks were less likely than whites to report participation in prostate cancer screening prior to diagnosis. Men without a prior history of screening were more likely to be diagnosed with advanced disease and/or more aggressive forms of prostate cancer. However, when men of either race had established relationships with a health care provider, the differences in prostate cancer stage at diagnosis went away.

"This evidence leads us to think that encouraging African-Americans to establish an ongoing relationship with a regular care provider may encourage more appropriate use of prostate cancer screening, and thus reduce racial disparities in prostate cancer diagnosis and treatment, which, by extension, may reduce disparities in prostate cancer deaths," Carpenter said.

James Mohler, M.D., chair of the department of urology at Roswell Park Cancer Institute in Buffalo, N.Y., and principal investigator of the study, said, "The goal of the study was to gain a deeper understanding of the role of racial disparities in prostate cancer outcomes. These findings suggest that differences in screening result from inconsistent or poorer quality interaction between an African-American man and the American health care system. If the interaction is poor, the care giver may not 'get around' to discussing or offering preventive health care, such as prostate cancer screening. Improving the interaction between all men, and especially African-American men, and their primary care givers should reduce prostate cancer deaths in all men and decrease the racial disparity in prostate deaths in African-American men." Mohler is a member of UNC Lineberger Comprehensive Cancer Center.

Carpenter added, "Factors in health care systems, including setting and continuity of care, may hinder the development of physician-patient relationships, and possibly preclude discussions beyond the immediate medical issue at hand, including discussions of preventive health and preferences in use of early detection. These factors and relationships can influence whether there are discussions beyond the immediate medical issue at hand, including discussions of preventive health and preferences in use of health care services such as prostate cancer screening."
Other UNC authors include Paul Godley, M.D., Jeannette Bensen, Ph.D., Merle Mishel, Ph.D., and Timothy Finnegan, M.D. Other authors include the study's co-principal investigator, Elizabeth Fontham, Ph.D., from the Louisiana State University Health Science Center in New Orleans.

The research was supported by the U.S. Department of Defense and the National Cancer Institute.

University of North Carolina Health Care

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to